ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400
Debt
Debt-to-Equity Ratio-11.28
Current Ratio3.17
Quick Ratio3.15
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-60.47%
Return on EquityN/A
Return on Assets-17.16%
Miscellaneous
Employees459
Outstanding Shares194,390,000
Market Cap$0.00
Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
How were Ariad Pharmaceuticals' earnings last quarter?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) issued its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to analysts' expectations of $60.64 million. The company's revenue was up 133.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Ariad Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ariad Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Ariad Pharmaceuticals been receiving favorable news coverage?
Media coverage about ARIA stock has trended positive this week, according to Accern. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a media sentiment score of 0.28 on Accern's scale. They also assigned news coverage about the pharmaceutical company an impact score of 45.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Ariad Pharmaceuticals?
Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ariad Pharmaceuticals' stock price today?
One share of ARIA stock can currently be purchased for approximately $23.99.
How can I contact Ariad Pharmaceuticals?
Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.
MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
